Rafferty Asset Management
RYTM icon

Rafferty Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Rafferty Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.36M Sell
50,105
-5,421
-10% -$527K 0.02% 434
2025
Q4 		$5.94M Sell
55,526
-208
-0.4% -$22.1K 0.02% 383
2025
Q3 		$5.63M Buy
55,734
+4,123
+8% +$383K 0.02% 401
2025
Q2 		$3.26M Sell
51,611
-6,121
-11% -$375K 0.01% 489
2025
Q1 		$3.06M Buy
57,732
+7,338
+15% +$407K 0.01% 473
2024
Q4 		$2.82M Sell
50,394
-14,182
-22% -$783K 0.01% 544
2024
Q3 		$3.38M Sell
64,576
-7,986
-11% -$383K 0.01% 500
2024
Q2 		$2.98M Sell
72,562
-146,095
-67% -$5.83M 0.01% 532
2024
Q1 		$9.47M Buy
218,657
+97,003
+80% +$4.25M 0.04% 281
2023
Q4 		$5.59M Sell
121,654
-41,150
-25% -$1.3M 0.02% 422
2023
Q3 		$3.73M Sell
162,804
-96,540
-37% -$2.16M 0.02% 463
2023
Q2 		$4.28M Buy
259,344
+4,134
+2% +$74.6K 0.02% 450
2023
Q1 		$4.55M Sell
255,210
-50,803
-17% -$1.28M 0.03% 402
2022
Q4 		$8.91M Buy
306,013
+43,725
+17% +$1.12M 0.07% 213
2022
Q3 		$6.43M Buy
+262,288
New +$4.88M 0.07% 261
2022
Q1 		– Sell
-111,594
Closed -$1.11M – 1313
2021
Q4 		$1.11M Buy
111,594
+28,740
+35% +$323K 0.01% 820
2021
Q3 		$1.08M Sell
82,854
-167
-0.2% -$2.55K 0.01% 791
2021
Q2 		$1.63M Sell
83,021
-38,646
-32% -$802K 0.01% 742
2021
Q1 		$2.59M Buy
121,667
+111,888
+1,144% +$3.25M 0.02% 559
2020
Q4 		$291K Sell
9,779
-902
-8% -$22.9K ﹤0.01% 824
2020
Q3 		$231K Buy
+10,681
New +$245K ﹤0.01% 892
2020
Q1 		– Sell
-20,847
Closed -$479K – 767
2019
Q4 		$479K Sell
20,847
-7,134
-25% -$158K 0.01% 694
2019
Q3 		$604K Buy
27,981
+10,794
+63% +$232K 0.01% 638
2019
Q2 		$378K Buy
17,187
+3,071
+22% +$77.6K 0.01% 728
2019
Q1 		$387K Buy
+14,116
New +$406K 0.01% 703

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Rafferty Asset Management's RYTM Position: Q1 2026 in Review

Rafferty Asset Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 9.8% in Q1 2026, selling an estimated $527K and leaving 50,105 shares worth $4.36M. The position accounts for 0.02% of the portfolio, ranked #434.

Rafferty Asset Management first reported a position in RYTM in Q1 2019 and has held it in 25 quarters since. The position peaked at $9.47M in Q1 2024. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Rafferty Asset Management held 50,105 shares of Rhythm Pharmaceuticals worth $4.36M as of Q1 2026.
  • Rafferty Asset Management sold 5,421 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $527K.
  • Rhythm Pharmaceuticals made up 0.02% of Rafferty Asset Management's portfolio in Q1 2026, its #434 holding.
  • Rafferty Asset Management first reported a position in Rhythm Pharmaceuticals in Q1 2019 and has held it in 25 quarters since.
  • Rafferty Asset Management's Rhythm Pharmaceuticals position peaked at $9.47M in Q1 2024.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.